PEDIATRIC ONCOLOGY GROUP - UNIVERSITY OF FLORIDA

儿科肿瘤学组 - 佛罗里达大学

• 批准号: 3557045
• 负责人: SAMUEL GROSS
• 金额: $ 10.88万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 1981
• 资助国家: 美国
• 起止时间: 1981-01-01 至 1995-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557045
• 关键词: child (0-11); clinical trials; cooperative study; human subject; human therapy evaluation; pediatric neoplasm /cancer

The past five years in POG saw stablization and refinement in pre-existing studies and entirely new approaches to cancer care. Such endeavors mandate divisions of labor within groups and institutions in terms of accrual, scientific input, and institutional features. Aggressive up-front therapy is the most effective regimen for most malignant processes. Single agent therapy for resistant disease is eventually fruitless, and genetic information adapted into the fabric of therapy is becoming increasingly more vital to the development of effective treatment programs. At the U of F we have (1) increased basic science endeavors so as to address principles of therapy, and (2) developed FDA approved marrow purging techniques utilizing monoclonalantibodies and magnetic microspheres for treating high risk neuroblastoma, which resulted in a five fold increase in DFS. These pilot studies are now group-wide projects. These techniques when applied to treatment of cALLa were found to be wanting and a reapprisal was obviously mandated. Combination MoAb-microspheres in concert with chemotherapy purging is the reasonable choice for all such patients in whom allografting is not feasible. Our successful, unrelated donor marrow transplant program is available for group-wide use. We have competed the basic science for an approach designed to distinguish between Graft vs. Host Disease and Graft vs. Leukemia using MoAb to CD 8. Such studies have been successfully carried out in adults using anti-CD 8 and C. We have shown that high risk Ewing's sarcoma can be effectively treated with megadose therapy and marrow rescue and it, too, is ready for group-wide use. Our data on osteosarcoma therapy with four drug rotational therapy are no better than any other best therapy. The next o.s. study will include megadose therapy with marrow rescue prior to surgery. We have responded to POG's request to initiate bone marrow transplantation for brain tumors and lymphomas. We will continue to develop (1) long term marrow self-renewing culture systems, (2) growth factor studies and (3) polymerase chain reaction studies (for MRD detection) whilst actively participating in all POG programs as attested by our increased accural over the five year span during which time we absorbed by the Jacksonville (University Hospital/Nemours Clinic) institutions into our program, added a satellite (Miami Children's Hospital), and an affiliate, University of South Carolina at Charleston, efforts designed to be certain that no child with cancer is denied best available medicine at best available institutions.

过去的五年在POG中看到了预先存在的稳定和改进 研究和全新的癌症护理方法。 这样的努力授权 从应计的团体和机构内部的劳动划分， 科学投入和机构特征。 积极的前期治疗 是大多数恶性过程中最有效的方案。 单代理 抗性疾病的治疗最终是徒劳的，遗传 适应治疗结构的信息越来越多 对于制定有效的治疗计划至关重要。 在 如果我们有（1）增加了基础科学的努力，以解决原则 疗法，（2）开发了FDA批准的骨髓清除技术 利用单克隆抗体和磁性微球来处理高 风险神经母细胞瘤，导致DFS增加了五倍。 这些 试点研究现在是整个小组的项目。 应用这些技术时 发现Calla的治疗是想要的，并且重新计时是 显然是强制性的。 组合摩押微环与 对于所有此类患者来说，化学疗法清除是合理的选择 同属不可行。 我们成功的，无关的捐助者骨髓 移植程序可用于整个范围内使用。 我们竞争了 旨在区分移植V的方法的基础科学。 宿主疾病和移植与白血病使用Moab到CD 8。 使用抗CD 8和C成功地在成年人中进行了 表明高风险尤因的肉瘤可以有效地治疗 巨糖疗法和骨髓救援，它也准备在整个小组中 使用。 我们使用四种药物旋转治疗的骨肉瘤治疗的数据 没有任何其他最佳疗法。 下一个O.S.研究会 在手术前将毛糖治疗与骨髓救援一起进行。 我们有 回应了POG启动骨髓移植的要求 脑肿瘤和淋巴瘤。 我们将继续发展（1）长期 骨髓自我更新培养系统，（2）生长因子研究和（3） 聚合酶链反应研究（用于MRD检测），而积极地 参加所有POG计划，这是我们增加的兴趣所证明的 在此期间我们被杰克逊维尔吸收的五年跨度 （大学医院/Nemours诊所）机构加入了我们的计划 卫星（迈阿密儿童医院）和分支机构，大学 查尔斯顿的南卡罗来纳州，旨在确定没有孩子的努力 癌症被剥夺了最佳可用药物的最佳用药 机构。